Guggenheim analyst Eddie Hickman lowered the firm’s price target on ProMIS Neurosciences (PMN) to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences’ Alzheimer’s candidate, PMN310, is rapidly advancing toward key clinical milestones, which keeps the company on track for two pivotal data readouts in 2026, the analyst tells investors following the company’s Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- Promising Advancements in Alzheimer’s Research and Strong Financial Position Support Buy Rating for ProMIS Neurosciences
- ProMIS Neurosciences Reports Increased R&D Costs and Net Loss
- ProMIS Neurosciences reports Q3 EPS (24c) vs 31c last year
- PMN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ProMIS Neurosciences Advances Alzheimer’s Study with PMN310